Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|1|79-89

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.1, 2015-01, pp. : 79-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 108-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients

By Di Biagio Antonio  

Journal of Infection and Chemotherapy, Vol. 18, Iss. 4, 2012-08 ,pp. : 587-590

Springer Publishing Company

Access to resources Recommend Favorite

P226: Turquoise‐III: safety and efficacy of 12‐week ribavirin‐free treatment for patients with HCV genotype 1b and cirrhosis

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 134-135

John Wiley & Sons Inc

Access to resources Recommend Favorite